| Quarterly Financials | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 80 | 104 | 80 | 103 | 108 | 117 | 134 |
| Expenses | 64 | 80 | 59 | 77 | 77 | 95 | 104 |
| EBITDA | 16 | 24 | 21 | 26 | 31 | 22 | 30 |
| Operating Profit % | 19 % | 22 % | 26 % | 24 % | 25 % | 10 % | 20 % |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 |
| Interest | 3 | 3 | 5 | 5 | 6 | 5 | 5 |
| Profit Before Tax | 10 | 18 | 14 | 16 | 21 | 21 | 27 |
| Tax | 3 | 3 | 3 | 3 | 4 | 3 | 5 |
| Net Profit | 7 | 14 | 11 | 13 | 16 | 18 | 21 |
| EPS in ₹ | 4.01 | 8.03 | 3.39 | 2.78 | 5.04 | 3.81 | 4.60 |
Senores Pharmaceuticals
Senores Pharmaceuticals
742.85
-7.35
(-0.98%)
Key Fundamentals
Market Cap
3,421.09 Cr
EPS
16.12
PE Ratio
50.38
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
755.50
52 Week Low
435.25
PB Ratio
4.40
Debt to Equity
0.58
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from4 analysts
Actual
Company News
View All News
Senores Pharmaceuticals has invested $2 million in its wholly owned US subsidiary, Senores Pharmaceuticals Inc. The investment represents the company's capital allocation to its American operations.
Senores Pharmaceuticals Completes Acquisition of 8,454 Equity Shares in Havix Group Inc.
Sep 12, 2025
Sep 12, 2025Senores Pharmaceuticals Limited has completed its acquisition of 8,454 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals. The company had previously acquired 7,914 shares directly, while the remaining 540 shares were acquired through its wholly owned US subsidiary, Senores Pharmaceuticals Inc. The acquisition of the final 540 shares through the subsidiary was necessary due to certain regulatory approval requirements from the Reserve Bank of India. The transaction, which began with earlier intimations in March 2025, is now fully completed.
Senores Pharmaceuticals Acquires Two USFDA-Approved ANDAs from Teva Pharmaceuticals USAAug 12, 2025
Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals Inc. USA, has signed an agreement to acquire two USFDA-approved Abbreviated New Drug Applications (ANDAs) from Teva Pharmaceuticals USA Inc. The addressable opportunity of the acquired ANDAs in the USA is approximately USD 38 million according to IQVIA data and USD 120 million according to Symphony data. The acquisition will be funded through proceeds from the company's Initial Public Offer, aligning with the stated IPO objectives. Senores Pharmaceuticals operates as a global research-driven pharmaceutical company with manufacturing facilities in Atlanta, US and Chhatral, India, maintaining a current portfolio of 70 ANDA and 27 CMO/CDMO commercial products permitted for US distribution.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,691.80 | #1 4,05,919.49 | 39.01 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 61.71 | |
6,600.00 | 1,75,209.26 | 75.90 | 9,712.00 | 18.67 | 2,191 | 26.74 | 72.60 | |
1,647.60 | 1,33,085.56 | 24.96 | 28,409.50 | 7.12 | 5,291 | 9.88 | 60.63 | |
3,621.60 | 1,22,571.40 | 60.69 | 11,539.40 | 6.99 | 1,911 | 19.91 | 53.74 | |
1,282.80 | 1,07,064.25 | #1 18.74 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.97 | |
1,009.40 | 1,01,569.26 | 21.36 | 23,511.00 | 18.55 | 4,615 | 2.60 | 45.37 | |
2,445.70 | 1,00,948.34 | 52.80 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 47.04 | |
1,950.80 | 89,103.67 | 23.85 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.82 | |
5,551.00 | 66,370.53 | 28.44 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.11 | |
1,103.90 | 64,114.69 | 19.03 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.87 |
Growth Rate
Revenue Growth
92.13 %
Net Income Growth
78.29 %
Cash Flow Change
-78.68 %
ROE
-49.15 %
ROCE
1.63 %
EBITDA Margin (Avg.)
27.75 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 59 | 131 | 622 | 1,227 |
| Fixed Assets | 7 | 27 | 235 | 301 |
| Current Assets | 27 | 51 | 251 | 722 |
| Capital Work in Progress | 8 | 35 | 97 | 173 |
| Investments | 15 | 17 | 0 | 0 |
| Other Assets | 29 | 53 | 289 | 754 |
| Total Liabilities | 59 | 131 | 622 | 1,227 |
| Current Liabilities | 10 | 52 | 248 | 241 |
| Non Current Liabilities | 13 | 34 | 143 | 174 |
| Total Equity | 37 | 46 | 232 | 812 |
| Reserve & Surplus | 28 | 36 | 174 | 740 |
| Share Capital | 9 | 10 | 31 | 46 |
Cash Flow
| Cash Flow | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 2 | -3 | 8 | 98 |
| Investing Activities | -24 | -48 | -54 | -430 |
| Operating Activities | -10 | -1 | -26 | -46 |
| Financing Activities | 37 | 46 | 87 | 573 |
Share Holding
| % Holding | Jul 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 66.66 % | 45.76 % | 45.76 % | 45.77 % | 45.78 % | 45.80 % |
| FIIs | 0.00 % | 5.51 % | 4.25 % | 4.17 % | 3.67 % | 4.28 % |
| DIIs | 0.00 % | 18.61 % | 11.78 % | 9.65 % | 9.51 % | 8.61 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 27.88 % | 28.71 % | 31.43 % | 31.44 % | 31.09 % |
| Others | 33.34 % | 2.23 % | 9.49 % | 8.97 % | 9.60 % | 10.22 % |
| No of Share Holders | 177 | 43,707 | 43,707 | 37,653 | 36,389 | 34,917 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 23 Jan 2025 |  Quarterly Result Announcement | NA | 23 Jan 2025 | 530.80 | 498.50 |
| 15 May 2025 | Quarterly Result Announcement | NA | 15 May 2025 | 483.75 | 541.05 |
| 23 Jul 2025 | Quarterly Result Announcement | NA | 23 Jul 2025 | 617.55 | 616.35 |
| 18 Sept 2025 |  Annual General Meeting | NA | 18 Sept 2025 | 717.85 | 689.25 |
Announcements
Intimation For Change In Email Address Of MUFG Intime India Private Limited Registrar And Share Transfer Agent (RTA) Of The CompanyOct 08, 2025
Oct 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 18, 2025
Sep 18, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 18, 2025
Sep 18, 2025Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations 2015.Sep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 12, 2025
Sep 12, 2025Reg. 34 (1) Annual Report.Sep 05, 2025
Sep 05, 2025Re-Scheduling Of The Analyst / Institutional Investor Meetings Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 02, 2025
Sep 02, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 01, 2025
Sep 01, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 28, 2025
Aug 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 28, 2025
Aug 28, 2025Notice Of Eighth (8Th) Annual General Meeting To Be Held On September 18 2025Aug 26, 2025
Aug 26, 2025Reg. 34 (1) Annual Report.Aug 26, 2025
Aug 26, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Aug 25, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Aug 25, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Aug 25, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Aug 25, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Aug 25, 2025Cancellation Of Analyst / Institutional Investor Meetings Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 30, 2025
Jul 30, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 30, 2025
Jul 30, 2025Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 23, 2025
Jul 23, 2025Financial Results For Quarter Ended On June 30 2025Jul 23, 2025
Jul 23, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On July 23 2025Jul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 19, 2025
Jul 19, 2025Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025And To Transact Other Business MattersJul 17, 2025
Jul 17, 2025Resubmission Of Intimation For Issuance Of The Corporate Guarantee Dated July 10 2025Jul 14, 2025
Jul 14, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 10, 2025
Jul 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Update In Respect Of Our Earlier Intimations Dated March 11 2025 March 12 2025 And April 22 2025 Pursuant To Regulation 30 Of The SEBI (LODR) Regulations 2015Jun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Appointment Of Internal Auditors For FY 2025-26Jun 02, 2025
Jun 02, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On June 02 2025Jun 02, 2025
Jun 02, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2025
May 20, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bank of India Multi Cap Fund Direct-Growth | 0.87% | -15000 | -0.14% | -0.13% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.14% | 162 | 0.06% | 0.06% | |
| Bank of India Mid & Small Cap Equity & Debt Fund Direct-Growth | 0.54% | 0 | -0.01% | -0.01% | |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth | 0.71% | 0 | -0.01% | -0.02% | |
 Mahindra Manulife Balanced Advantage Fund Direct - Growth | 0.81% | 0 | 0.00% | 0.01% | |
| Mahindra Manulife Large & Mid Cap Fund Direct - Growth | 1.73% | 0 | -0.03% | 0.14% |
Technical Indicators
RSI(14)
Neutral 60.25
ATR(14)
Less Volatile 25.35
STOCH(9,6)
Neutral 54.90
STOCH RSI(14)
Neutral 64.54
MACD(12,26)
Bullish 2.08
ADX(14)
Weak Trend 20.72
UO(9)
Bearish 46.30
ROC(12)
Uptrend And Accelerating 3.02
WillR(14)
Overbought -7.48
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
